| Today's Top Story |  |  | | - EU extends approval of GSK's Votrient to soft-tissue sarcoma
The European Commission authorized GlaxoSmithKline to market Votrient, or pazopanib, to treat patients with advanced soft-tissue sarcoma who already received chemotherapy or whose disease advanced within a year after neoadjuvant treatment. The drug is also approved in the U.S. and Europe to treat advanced kidney cancer. PharmaTimes (U.K.) (8/8)        | Earn 3X rewards points when you fly with The Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
LEARN MORE AND APPLY |
  | Health Care & Policy | | | | - Pfizer, Janssen suspend Alzheimer's clinical trials
Pfizer and Janssen are discontinuing clinical testing of monoclonal antibody bapineuzumab in patients with mild to moderate forms of Alzheimer's disease after the drug failed to improve cognitive and functional performance in patients who do not have the APOE4 genotype. The drugmakers might test the therapy in patients with preclinical Alzheimer's, which some studies suggest is a more appropriate group. MedPage Today (free registration) (8/6), Reuters (8/7) - Amgen ends 2 trials of pancreatic cancer drug
Amgen stopped a Phase III study of pancreatic cancer drug candidate AMG479, or ganitumab, after reviewers said it is unlikely to help patients. The drugmaker said it will also halt a Phase II study of the treatment. "These disappointing results underscore the difficulty of treating pancreatic cancer, which remains an unmet medical need," said Sean Harper, head of research and development. Reuters (8/8) - Cell-based method explored for producing blood cells for transfusion
Researchers are using human stem cells to produce red blood cells, and the method has the potential to provide cells of any blood type for transfusion, according to a study published in the journal Stem Cells Translational Medicine. "We combined different cell-expansion protocols into a 'cocktail' that increased the number of cells we could produce by 10- to 100-fold," said Eric Bouhassira of the Albert Einstein College of Medicine. Yahoo!/HealthDay News (8/8) | Company & Financial News | | | | - Cambridge gets $12.5M to set up stem cell research facility
The University of Cambridge will establish a stem cell research center using $12.5 million from the Wellcome Trust and the U.K. Medical Research Council. The Wellcome Trust-MRC Cambridge Stem Cell Institute, which will bring together 30 research groups, will be located at the Cambridge Biomedical Research Campus in England. Bloomberg (8/8) | Industry Deals | | | | - Active and Teva plan late-stage trial of MS drug laquinimod
Active Biotech and Teva Pharmaceutical Industries will initiate a Phase III trial to assess the efficacy of investigational drug laquinimod in patients with relapsing-remitting multiple sclerosis. The CONCERTO trial, which could last as long as two years, will involve about 1,800 patients. Drug Store News (8/8)
| Food & Agriculture | | | | | Industrial & Environmental | | | | - Report: RFS waiver wouldn't have a big impact on corn prices
Altering the Renewable Fuel Standard is unlikely to affect ethanol demand and corn prices, and would set a "very negative precedent for future government endeavors" that need private-sector involvement, according to a report from Morgan Stanley. Even if the RFS were repealed, refiners would likely keep using ethanol because it is cheaper than regular gasoline, said Morgan Stanley analysts Vincent Andrews and Hussein Allidina. "Economics, not politics, drives ethanol use. Other than an outright ban on ethanol use, we do not believe that any policy change will materially impact ethanol demand, and therefore corn prices," they said. Bloomberg Businessweek (8/7) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | Actions are the seed of fate. Deeds grow into destiny."
--Harry S. Truman,
33rd U.S. president  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, August 08, 2012
- Tuesday, August 07, 2012
- Monday, August 06, 2012
- Friday, August 03, 2012
- Thursday, August 02, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment